Market Place
Sourcing Support
Nurix Therapeutics to Participate in Upcoming Investor Conferences
31 Oct 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Announces Presentations At 7th Annual TPD Summit
21 Oct 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Shares Positive BTK Degrader NX-5948 Trial Data
19 Oct 2024 //
GLOBENEWSWIRE
Nurix Expands Board With Drug Commercialization Expert Anil Kapur
16 Oct 2024 //
GLOBENEWSWIRE
Nurix Reports Q3 Fiscal 2024 Results And Corporate Update
11 Oct 2024 //
GLOBENEWSWIRE
Nurix Announces Presentations At ACR Convergence 2024
09 Oct 2024 //
GLOBENEWSWIRE
Nurix Announces Presentations At Discovery On Target Conference
30 Sep 2024 //
GLOBENEWSWIRE
Nurix To Attend ADC & Radiopharmaceuticals Partnering Summit
06 Sep 2024 //
GLOBENEWSWIRE
Nurix Therapeutics to Participate in Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Reports Q2 Fiscal 2024 Results And Corporate Updat
11 Jul 2024 //
GLOBENEWSWIRE
Nurix to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day
08 Jul 2024 //
GLOBENEWSWIRE
Nurix Presents Positive NX-5948 CLL Trial Results At EHA2024
16 Jun 2024 //
GLOBENEWSWIRE
Nurix Hosts Call On NX-5948 Phase 1 Data At EHA 2024
10 Jun 2024 //
GLOBENEWSWIRE
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
Nurix Therapeutics: New Chief Medical, Technical Officers Appointed
28 May 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Announces Board Chair Transition
20 May 2024 //
GLOBENEWSWIRE
Nurix Announces NX-5948 BTK Degrader Data At EHA 2024
14 May 2024 //
GLOBENEWSWIRE
Nurix At RBC Capital Healthcare Conference
07 May 2024 //
GLOBENEWSWIRE
Nurix Announces Closing of Public Offering, Underwriters` Option Exercise
16 Apr 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Announces Proposed Public Offering
11 Apr 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
11 Apr 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Reports Q1 2024 Financials, Corporate Update
10 Apr 2024 //
GLOBENEWSWIRE
Nurix Extends Collaboration with Sanofi for STAT6 Protein Degraders
09 Apr 2024 //
GLOBENEWSWIRE
Nurix Reports CNS Activity of NX-5948, BTK Degrader in Develop for Malignancies
09 Apr 2024 //
GLOBENEWSWIRE
Nurix Therapeutics to Participate in Upcoming Investor Conferences
03 Apr 2024 //
GLOBENEWSWIRE
Gilead dives deeper into Nurix protein degrader collab
02 Apr 2024 //
FIERCE BIOTECH
Nurix Therapeutics is Part of a Team of International Oncology Experts
25 Mar 2024 //
GLOBENEWSWIRE
Nurix Presents the Discovery First-in-Class CBL-B Inhibitor NX-1607
20 Mar 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127
11 Mar 2024 //
GLOBENEWSWIRE
Nurix gets BTK degrader back on track after FDA lifts hold
11 Mar 2024 //
FIERCE BIOTECH
Nurix Therapeutics to Participate in Upcoming Investor Conferences
06 Mar 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Announces Presentations at AACR 2024 Annual Meeting
05 Mar 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
15 Feb 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Announces Publication in the Journal Science
01 Feb 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948
16 Jan 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Outlines 2024 Strategic Priorities
08 Jan 2024 //
GLOBENEWSWIRE
Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Nurix Therapeutics Presents Positive Clinical Data from Its NX-5948 and NX-2127
11 Dec 2023 //
GLOBENEWSWIRE
Nurix Announces Webcast To Review Data from Phase 1 Trials of BTK Degraders
04 Dec 2023 //
GLOBENEWSWIRE
Nurix Therapeutics to Participate in Upcoming Investor Conferences
07 Nov 2023 //
GLOBENEWSWIRE
Nurix Therapeutics Announces Presentations at the 65th ASH Annual Meeting
02 Nov 2023 //
GLOBENEWSWIRE
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
01 Nov 2023 //
GLOBENEWSWIRE
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results
12 Oct 2023 //
GLOBENEWSWIRE
Nurix Announces Collaboration with Seagen Combining Leading Technologies
07 Sep 2023 //
GLOBENEWSWIRE
Nurix Therapeutics to Participate in Upcoming Investor Conferences
31 Aug 2023 //
GLOBENEWSWIRE
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results
13 Jul 2023 //
GLOBENEWSWIRE
Nurix Therapeutics Initiates Expansion of NX-2127 Phase 1b Trial
14 Jun 2023 //
GLOBENEWSWIRE
Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Conference
09 May 2023 //
GLOBENEWSWIRE
Nurix Presents Data at the (AACR) Meeting Highlighting Activity of its BTK
17 Apr 2023 //
GLOBENEWSWIRE
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results
13 Apr 2023 //
GLOBENEWSWIRE
Nurix to Participate in the 22nd Annual Needham Virtual Healthcare Conference
11 Apr 2023 //
GLOBENEWSWIRE
Gilead Sciences to exclusively license Nurix Therapeutics’ protein degrader
20 Mar 2023 //
PHARMACEUTICAL TECHNOLOGY
Nurix Therapeutics Announces Presentations at AACR
14 Mar 2023 //
GLOBENEWSWIRE
Nurix to Present at the Oppenheimer 33rd Annual Healthcare Conference
06 Mar 2023 //
GLOBENEWSWIRE
Nurix Reports Fourth Quarter and Fiscal Year 2022 Financial Results
09 Feb 2023 //
GLOBENEWSWIRE
Nurix Therapeutics to Participate in Upcoming Investor Conferences
08 Feb 2023 //
GLOBENEWSWIRE
Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline
09 Jan 2023 //
GLOBENEWSWIRE
Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
Nurix Announces Clearance of Investigational New Drug Application for NX-5948
15 Dec 2022 //
GLOBENEWSWIRE
Nurix Therapeutics Presents Positive Clinical Results from Novel BTK Degrader
12 Dec 2022 //
GLOBENEWSWIRE
